Clinical Trial: Risk Factors for Treatment Failure in Women With Detrusor Overactivity Receiving Combined Pharmacotherapy

U.S., Jan. 14 -- ClinicalTrials.gov registry received information related to the study (NCT07337252) titled 'Risk Factors for Treatment Failure in Women With Detrusor Overactivity Receiving Combined Pharmacotherapy' on Jan. 01.

Brief Summary: This study evaluated the outcomes of women with detrusor overactivity treated with combined pharmacotherapy to identify risk factors for treatment failure.

Study Start Date: June 01, 2022

Study Type: OBSERVATIONAL

Condition: Overactive Bladder

Intervention: DRUG: Combined pharmacotherapy

Combined pharmacotherapy with oral solifenacin 5 mg and mirabegron 25 mg once daily.

Recruitment Status: COMPLETED

Sponsor: Mackay Memorial Hospital

Information provided by (Responsible Party): Hui-Hsuan Lau...